Therapeuticsmd Story

<div class='circular--portrait' style='background:#006400;color: #F5FFFA;font-size:5em;'>T</div>
TXMD -- USA Stock  

USD 1.21  0.01  0.82%

Will avarage Therapeuticsmd analyst consensus change from Strong Buy? Therapeuticsmd is scheduled to announce its earnings today. The next earnings report is expected on the 5th of May 2021. The stock experiences above-average trading activities. As many retail investors are getting excited about healthcare space, it is fair to digest Therapeuticsmd outlook under the latest economic conditions. What exactly are Therapeuticsmd shareholders getting in April? The current consensus of 4 analysts on the firm is Strong Buy.
Published over a month ago
View all stories for Therapeuticsmd | View All Stories
Should you drop your Therapeuticsmd (NASDAQ:TXMD) positions because of the latest analyst consensus?
This firm currently holds 248.36 M in liabilities with Debt to Equity (D/E) ratio of 0.67, which is about average as compared to similar companies.
What is the right price you would pay to acquire a share of Therapeuticsmd? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated.
Please read more on our stock advisor page.

Watch out for price decline

Please consider monitoring Therapeuticsmd on a daily basis if you are holding a position in it. Therapeuticsmd is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Therapeuticsmd stock to be traded above the $1 level to remain listed. If Therapeuticsmd stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

What is happening with Therapeuticsmd this year

Annual and quarterly reports issued by Therapeuticsmd are formal financial statements that are published yearly and quarterly and sent to Therapeuticsmd stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Therapeuticsmd often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How Therapeuticsmd utilizes its cash?

To perform a cash flow analysis of Therapeuticsmd, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Therapeuticsmd is receiving and how much cash it distributes out in a given period. The Therapeuticsmd cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Therapeuticsmd Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (159.47 Million)

Breaking it down

Analysts have increased confidence in Therapeuticsmd as compared to a month ago. The current consensus of 4 analysts is Strong Buy.

Is Therapeuticsmd a risky opportunity?

Let's check the volatility. Therapeuticsmd is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Therapeuticsmd (NASDAQ:TXMD) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. purchasing a share of a Therapeuticsmd stock makes you a part-owner of that company.

Therapeuticsmd Current Consensus

Here is the latest trade recommendation based on an ongoing consensus estimate among financial analysis covering Therapeuticsmd. The Therapeuticsmd consensus assessment is calculated by taking the average estimates from all of the analysts covering Therapeuticsmd

Strong Buy
Strong Buy4100.0
Strong Sell00.0

Therapeuticsmd latest price dip can leaving shareholders with little time to react

Therapeuticsmd latest potential upside ascents over 7.1. Therapeuticsmd exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Therapeuticsmd individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Therapeuticsmd future systematic risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Therapeuticsmd's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Therapeuticsmd's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Bottom Line On Therapeuticsmd

Although some firms within the drug manufacturers?specialty & generic industry are still a little expensive, even after the recent corrections, Therapeuticsmd may offer a potential longer-term growth to shareholders. The inconsistency in the assessment between current Therapeuticsmd valuation and our trade advice on Therapeuticsmd is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Therapeuticsmd.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Therapeuticsmd. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to